Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5698232 | Clinical Oncology | 2014 | 5 Pages |
Abstract
The first-line standard treatment for diffuse large B-cell lymphoma (DLBCL) is the R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). It is associated with cardiotoxicity, which is why new treatment strategies are needed. Liposomial doxorubicin has been proven to reduce these side-effects, but until now a direct comparison regarding efficacy has not yet been published. We retrospectively assessed 364 consecutive DLBCL patients who underwent either R-CHOP (218; 60%) or R-COMP (doxorubicin replaced by non-pegylated liposomal doxorubicin; 146; 40%) in first line and compared outcome and survival. We provide evidence that both regimens induce a high and comparable number of complete remissions and that both are able to cure patients with DLBCL. Confirmatory data are needed.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
M. Mian, I. Wasle, G. Gamerith, P. Mondello, T. Melchardt, T. Jäger, W. Linkesch, M. Fiegl,